These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 37160689)

  • 21. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
    Su NY; Shi Q; Mei H; Hu J; Liu YX; Liu HN; Liu HQ; Guo Y; Wang XW; Lan CH
    Helicobacter; 2023 Oct; 28(5):e13003. PubMed ID: 37565458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
    Hu Y; Xu X; Ouyang YB; He C; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Lu NH; Zhu Y
    Helicobacter; 2022 Oct; 27(5):e12923. PubMed ID: 36036087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
    Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
    Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
    Veldhuyzen van Zanten S; Chiba N; Barkun A; Fallone C; Farley A; Cockeram A; Dallaire C; Simms L; Nicholls B
    Can J Gastroenterol; 2003 Sep; 17(9):533-8. PubMed ID: 14532926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan on the Eradication of Helicobacter pylori Infection.
    Huang J; Lin Y
    Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
    Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
    Horii T; Suzuki S; Takano C; Shibuya H; Ichijima R; Kusano C; Ikehara H; Gotoda T
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3314-3321. PubMed ID: 34107551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
    Yang J; Zhang Y; Fan L; Zhu YJ; Wang TY; Wang XW; Chen DF; Lan CH
    Am J Gastroenterol; 2019 Mar; 114(3):437-445. PubMed ID: 30807294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating
    Hu Y; Xu X; Liu XS; He C; Ouyang YB; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Zhu Y; Graham DY; Lu NH
    Front Immunol; 2022; 13():1049908. PubMed ID: 36726990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
    Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
    Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.